Wire · founder news, decoded · opportunities
FDA approves Sanofi drug delivered with Enable on-body device
FDA approved Sanofi's Sarclisa anticancer therapy delivered via Enable Injections' on-body wearable device (CirCLIQ), marking the first FDA-cleared on-body injector for cancer treatment. The approval follows Sanofi's $30m investment in Enable and enables subcutaneous administration as an alternative to intravenous infusion for multiple myeloma patients.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
You're building wearable drug delivery or oncology infrastructure: Sanofi just proved there's a large-volume cancer treatment market willing to move from IV chairs to at-home subcutaneous injection, and Enable is now the reference design that pharma companies will chase. The commercial play is not the device—it's becoming the delivery partner every oncology company needs to upgrade their franchise.
Read the full story at drugdeliverybusiness.com →
Topics: Digital Health · drug-delivery · medical-devices · oncology · regulatory-approval · wearable-tech · pharma-partnerships